Expression and significance of molecular biomarkers in esophageal carcinoma in different nationalities patients in Xinjiang

Zhang, L.; Sun, J.; Zhang, J.Q.; Yang, Minghui; Bai, Ge; Ma, Xiaoli

doi:10.4238/2014.july.24.21

Cited by 5 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have reported EGFR overexpression in 27-55% of esophageal and GEJ adenocarcinomas (24)(25)(26)(27). Wang et al demonstrated EGFR overexpression in 32% of patients and was correlated with higher tumor stage, lymph node metastasis, but failed to show correlation with shorter disease-free (DFS) or OS, which is in accordance with the results of our study (28).…”

Section: Discussionsupporting

confidence: 83%

EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma

Chan¹,

Alkhasawneh²,

Duckworth³

et al. 2016

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

Background: Targeted therapy with anti-human epidermal growth factor receptor-2 (HER2) monoclonal antibody in patients with HER2 overexpressed esophagogastric adenocarcinoma (EGA) improves survival; however, the effect is transient due to the development of resistance. Some studies suggest that cMet overexpression provides cross talk for epidermal growth factor receptor (EGFR) and HER2 inhibition. We sought to characterize the expression profile of the EGFR family and cMet receptors in untreated, resected EGA. and cMet expression scored as low (0, 1+) or high (2+, 3+). Demographic and tumor characteristics were compared using Fisher exact test. Kaplan-Meier curves and univariate analysis compared survival among different receptors. Results: Total 52 patients were included in the study with median age 66 years. High expression of EGFR (73%), HER2 (40%), HER3 (75%), HER4 (35%) and cMet (69%) was detected among the study group. HER3 and HER4 co-expression was found in 18 (35%) cases. Pan expression of all four EGFR family members with cMet was noted in only 17% of cases. On univariate analysis, tumor stage and depth correlated with survival, while cMet + HER3 +/-EGFR receptor co-expression trended towards a worse survival. Conclusions: EGFR family and cMet are frequently co-expressed in treatment naïve resected EGA or GEJ tumors. Although our data do not significantly show receptor status as a prognostic factor, the co-expression profiles support for further investigation to improve targeting of this signal transduction axis.

show abstract

Section: Discussionsupporting

confidence: 83%

EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma

Chan¹,

Alkhasawneh²,

Duckworth³

et al. 2016

J. Gastrointest. Oncol.

View full text Add to dashboard Cite

show abstract

“…In our study of previously untreated tumors, we noted a relatively high expression of EGFR receptor (73%). Previous studies have reported EGFR overexpression in 27-55% of esophageal and GEJ adenocarcinomas (24)(25)(26)(27). Wang et al demonstrated EGFR overexpression in 32% of patients and was correlated with higher tumor stage, lymph node metastasis, but failed to show correlation with shorter disease-free (DFS) or OS, which is in accordance with the results of our study (28).…”

Section: Discussionsupporting

confidence: 92%

EGFR family and c-Met expression profiles and prognostic significance in esophagogastric adenocarcinoma.

Chan

Alkhasawneh

Duckworth

et al. 2013

JCO

View full text Add to dashboard Cite

e15108 Background: Targeted therapy of HER2 overexpression in patients with esophagogastric adenocarcinoma (EGA) improves survival; however, the effect is transient due to the development of resistance. Targeting of EGFR alone in EGA was not active. cMet overexpression is suggested to be a possible resistance pathway for EGFR and HER-2 inhibition. We characterized the expression profile of the EGFR family of receptors and cMet as well as their prognostic significance in EGA. Methods: This retrospective analysis included all patients (pts) with EGA who underwent primary resection at the University of Florida from 2001 to 2011 without neoadjuvant therapy. Demographics, risk factors, tumor features, and outcome data were analyzed. Central blinded immunohistochemistry (IHC) was performed on paraffin embedded tumor specimens with EGFR, HER2, HER3, HER4 and cMet expression scored as low (0, 1+) or high expression (2+, 3+). Descriptive statistics, Fisher exact test, Cox regression and Kaplan-Meier methods were used for statistical analyses. Results: 52 pts (42 M/10 F) were analyzed with median age 66 years (37-83). Most tumors (58%) were stage I (T1N0). Receptors expression profiles and their associations are presented in the Table. High HER3-HER4 co-expression was found in 35% of cases (p = 0.002). Univariate analysis did not show significant correlation of age, tumor differentiation, BMI, tobacco use and receptor expression with survival. Stage was the only variable that correlated significantly with survival (p=0.02). Conclusions: This is the first study to our knowledge examining the EGFR family expression relationships and cMet in treatment naïve resected EGA tumors. Associations between receptor expression patterns are of clinical interest for rational development of multi-targeted inhibition. Although our data do not significantly show receptor status as a prognostic factor, some receptor expression associations suggest trends towards worse survival. Larger studies are warranted for further investigation. [Table: see text]

show abstract

“…For domain 2 (“Study Attrition”), 73 original studies showed a low risk of bias because of the high follow-up rate for study participants. Seven original studies had moderate bias in domain 2 due to missing data on participants that were lost to follow-up [ 19 – 25 ]. There was a high risk of bias in domain 2 in 2 studies because of high loss to follow-up rates (50 and 23%) [ 11 , 26 ].…”

Section: Resultsmentioning

confidence: 99%

Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review

Wang

Chen

et al. 2017

Chin J Cancer

View full text Add to dashboard Cite

BackgroundEsophageal squamous cell carcinoma (ESCC) is an aggressive malignancy, with a high incidence and poor prognosis. In the past several decades, hundreds of proteins have been reported to be associated with the prognosis of ESCC, but none has been widely accepted to guide clinical care. This study aimed to identify proteins with great potential for predicting prognosis of ESCC.MethodsWe conducted a systematic review on immunohistochemical (IHC) prognostic markers of ESCC according to the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Guidelines. Literature related to IHC prognostic markers of ESCC were searched from PubMed, Embase, Web of Science, and Cochrane Library until January 30th, 2017. The risk of bias of these original studies was evaluated using the Quality in Prognosis Studies (QUIPS) tool.ResultsWe identified 11 emerging IHC markers with reproducible results, including eight markers [epidermal growth factor receptor (EGFR), Cyclin D1, vascular endothelial growth factor (VEGF), Survivin, Podoplanin, Fascin, phosphorylated mammalian target of rapamycin (p-mTOR), and pyruvate kinase M2 (PKM2)] indicating unfavorable prognosis and 3 markers (P27, P16, and E-cadherin) indicating favorable prognosis of ESCC.ConclusionStrong evidence supports that these 11 emerging IHC markers or their combinations may be useful in predicting prognosis and aiding personalized therapy decision-making for ESCC patients.Electronic supplementary materialThe online version of this article (doi:10.1186/s40880-017-0232-5) contains supplementary material, which is available to authorized users.

show abstract

Expression and significance of molecular biomarkers in esophageal carcinoma in different nationalities patients in Xinjiang

Cited by 5 publications

References 23 publications

EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma

EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma

EGFR family and c-Met expression profiles and prognostic significance in esophagogastric adenocarcinoma.

Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review

Contact Info

Product

Resources

About